Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00076089
Status:
COMPLETED
Last Update Posted:
2016-12-02
First Post:
2004-01-13
Brief Title:
OPUS Study Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease BY217M2-111
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease A 52-week Multicenter Double-blind Study With 500 mcg Roflumilast Once Daily Versus Placebo
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease COPD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None